Literature DB >> 26380427

Relationship Between Severity of Illness and Length of Stay on Costs Incurred During a Pediatric Critical Care Hospitalization.

Benson S Hsu, Saquib Lakhani, Thomas B Brazelton.   

Abstract

OBJECTIVE: To estimate the impact of severity of illness and length of stay on costs incurred during a pediatric intensive care unit (PICU) hospitalization. STUDY
DESIGN: This is a retrospective cohort study at an academic PICU located in the U.S. that examined 850 patients admitted to the PICU from Jan. 1 to Dec. 31, 2009. The study population was segmented into three severity levels based on pediatric risk of mortality (PRISM) III scores: low (PRISM score 0), medium (PRISM score 1-5), and high (PRISM score greater than 5). Outcome measures were total and daily PICU costs (2009 U.S. dollars).
RESULTS: Eight hundred and fifty patients were admitted to the PICU during the study period. Forty-eight patients (5.6 percent) had incomplete financial data and were excluded from further analysis. Mean total PICU costs for low (n = 429), medium (n = 211), and high (n = 162) severity populations were $21,043, $37,980, and $55,620 (p < 0.001). Mean daily PICU costs for the low, medium, and high severity groups were $5,138, $5,903, and $5,595 (p = 0.02).
CONCLUSIONS: Higher severity of illness resulted in higher total PICU costs. Interestingly, although daily PICU costs across severity of illness showed a statistically significant difference, the practical economic difference was minimal, emphasizing the importance of length of stay to total PICU costs. Thus, the study suggested that reducing length of stay independent of illness severity may be a practical cost control measure within the pediatric intensive care setting.

Entities:  

Mesh:

Year:  2015        PMID: 26380427

Source DB:  PubMed          Journal:  S D Med        ISSN: 0038-3317


  1 in total

1.  Relationship between pediatric intensive care unit length of stay and 24-h unplanned readmission rate.

Authors:  Moodakare Ashwini Bhat; Gerardo Soto-Campos; Matthew C Scanlon
Journal:  Health Serv Res       Date:  2022-02-24       Impact factor: 3.734

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.